Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saby George

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
JAMA Oncology|June 1, 2016
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical TrialSaby George, Robert J Motzer, Hans J Hammers, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instabilityYuanquan Yang, Rohit K Jain, Sean T Glenn, et al.
The Prostate|December 20, 2016
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate CancerAjjai Alva, Luke Nordquist, Stephanie Daignault, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyAli Reza Golshayan, Saby George, Daniel Y Heng, et al.
Journal of Cancer Epidemiology|January 11, 2017
Role of Private Enterprise in Cancer Control in Low to Middle Income CountriesChukwumere E Nwogu, Martin Mahoney, Ifeoma Okoye, et al.
Urology|April 29, 2014
High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experienceMichael Hanzly, Ahmed Aboumohamed, Naveen Yarlagadda, et al.
Clinical Genitourinary Cancer|October 1, 2008
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinomaSaby George, Robert Dreicer, Jessie J L Au, et al.
The Lancet. Oncology|January 20, 2019
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trialDavid Cella, Viktor Grünwald, Bernard Escudier, et al.
Cancer|February 10, 2024
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)Celestia S Higano, Sabina Dizdarevic, John Logue, et al.
Oncoimmunology|December 8, 2018
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumabSaby George, Antonios Papanicolau-Sengos, Felicia L Lenzo, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
JAMA Oncology|June 1, 2016
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical TrialSaby George, Robert J Motzer, Hans J Hammers, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instabilityYuanquan Yang, Rohit K Jain, Sean T Glenn, et al.
The Prostate|December 20, 2016
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate CancerAjjai Alva, Luke Nordquist, Stephanie Daignault, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyAli Reza Golshayan, Saby George, Daniel Y Heng, et al.
Journal of Cancer Epidemiology|January 11, 2017
Role of Private Enterprise in Cancer Control in Low to Middle Income CountriesChukwumere E Nwogu, Martin Mahoney, Ifeoma Okoye, et al.
Urology|April 29, 2014
High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experienceMichael Hanzly, Ahmed Aboumohamed, Naveen Yarlagadda, et al.
Clinical Genitourinary Cancer|October 1, 2008
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinomaSaby George, Robert Dreicer, Jessie J L Au, et al.
The Lancet. Oncology|January 20, 2019
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trialDavid Cella, Viktor Grünwald, Bernard Escudier, et al.
Cancer|February 10, 2024
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)Celestia S Higano, Sabina Dizdarevic, John Logue, et al.
Oncoimmunology|December 8, 2018
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumabSaby George, Antonios Papanicolau-Sengos, Felicia L Lenzo, et al.
Pageof 10